Medical Research Institute of New Zealand, , Wellington, New Zealand.
Thorax. 2013 Nov;68(11):1066-7. doi: 10.1136/thoraxjnl-2013-203724. Epub 2013 Jun 6.
The findings of the Understanding Potential Long-term Impacts on Function with Tiotropium (UPLIFT) study may be poorly generalisable to tiotropium use in clinical practice.
An audit of 226 patients admitted to Wellington Hospital with a chronic obstructive pulmonary disease exacerbation determined the proportion of patients prescribed tiotropium on discharge that would have been ineligible for inclusion in the UPLIFT study.
Among 100 patients prescribed tiotropium, 38/100; 38% (95% CI 28.5% to 48.3%) would have been ineligible for UPLIFT at the time of the hospital discharge due to recent cardiovascular comorbidity or moderate to severe renal impairment.
The UPLIFT findings have limited generalisability to over a third of patients prescribed tiotropium following a hospital admission with a chronic obstructive pulmonary disease exacerbation in New Zealand.
理解噻托溴铵对功能的潜在长期影响（UPLIFT）研究的结果可能无法很好地推广到噻托溴铵在临床实践中的应用。
对惠灵顿医院因慢性阻塞性肺疾病急性加重而入院的 226 名患者进行审核，确定出院时开具噻托溴铵处方的患者中，有多少比例不符合 UPLIFT 研究的入选标准。
在 100 名开具噻托溴铵处方的患者中，有 38/100；38%（95%CI 28.5%至 48.3%）由于近期心血管合并症或中重度肾功能损害，在出院时不符合 UPLIFT 的入选标准。
在新西兰，超过三分之一的慢性阻塞性肺疾病急性加重患者在住院后开具噻托溴铵治疗，UPLIFT 的研究结果对这些患者的适用性有限。
